Appendix D: Biomarkers Figure | Sodium Intake in Populations: Assessment of Evidence |The National Academies Press
Optimized sensitive and inexpensive method to measure D-lactate as a surrogate marker of methylglyoxal fluxes in metabolically relevant contexts - ScienceDirect
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases
Statistical evaluation of surrogate markers: Validity, efficiency, and sensitivity
Surrogate Endpoints and Biomarkers | Basicmedical Key
Surrogate Markers for Cardiovascular Disease | Circulation
Reasons for failure of surrogate markers in predicting endpoints.... | Download Scientific Diagram
Diagnostics | Free Full-Text | Circulating Monocyte Count as a Surrogate Marker for Ventricular-Arterial Remodeling and Incident Heart Failure with Preserved Ejection Fraction
What Do We Know About Surrogate Markers and Disease Outcomes? (Slides with Transcript)
Surrogate markers of infection: interrogation of the immune system | Biomarkers in Medicine
Table I from Surrogate markers in HIV disease. | Semantic Scholar
Surrogate endpoints in clinical trial
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors | Cardiovascular Diabetology | Full Text
FDA Facts: Biomarkers and Surrogate Endpoints | FDA
PPT - Surrogate Markers and its role in the Drug Development Process PowerPoint Presentation - ID:533855
Surrogate Markers of Chronic Allograft Nephropathy in Man - ppt download
Surrogate markers for GHB exposure in cell lines / 978-3-330-03856-1 / 9783330038561 / 333003856X
Surrogate Markers - TriageMethod
Magnetic Resonance Elastography as Surrogate Marker of Interstitial Fibrosis in Kidney Transplantation: A Prospective Study | American Society of Nephrology
Surrogate Markers and its role in the Drug Development Process - ppt video online download
Imaging as a surrogate marker of drug efficacy in cardiovascular disease | Heart
The use of surrogate end points in cardiovascular disease and diabetes - The British Journal of Cardiology
![Therapeutics Initiative | [92] The limitations and potential hazards of using surrogate markers](https://www.ti.ubc.ca/wordpress/wp-content/uploads/2015/10/92.jpg "Therapeutics Initiative | [92] The limitations and potential hazards of using surrogate markers")
Therapeutics Initiative | [92] The limitations and potential hazards of using surrogate markers
